WORLD'S LARGEST MARKET RESEARCH RESOURCE — 1,519,265 REPORTS

 
 
• SEARCH FOR A REPORT

Viewing report

Search
Enter keywords, a title or a report id number below.
Advanced

• ORDER BY FAX

Order By Fax

• SELECT SITE CURRENCY

Select a currency for use throughout the site



  • Electronic (PDF) Information Icon
  • CD ROM Information Icon
  • Hard Copy Information Icon
  • Site License Information Icon
  • Enterprisewide Information Icon
Live Chat Live Help Software for Website

Global Atopic Dermatitis Drug Pipeline Capsule - 2012

Fore Pharma, January 2012, Pages: 13

Fore Pharma’s latest report ‘Global Atopic Dermatitis Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global atopic dermatitis drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the atopic dermatitis drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Atopic Dermatitis: Overview
- Atopic Dermatitis Drug Pipeline Overview
- Atopic Dermatitis Phase 3 Clinical Trial Drug Pipeline Insights
- Atopic Dermatitis Phase 2 Clinical Trial Drug Pipeline Insights
- Atopic Dermatitis Phase 1 Clinical Trial Drug Pipeline Insights
- Atopic Dermatitis Preclinical Research Drug Pipeline Insights
- Atopic Dermatitis Drug Discovery Pipeline Insights
- Geographic Landscape of Atopic Dermatitis R&D Activities
- Atopic Dermatitis R&D Activities in North America
- Atopic Dermatitis R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Atopic Dermatitis Drug Market

1. Atopic Dermatitis: Disease Definition
2. Atopic Dermatitis Drug Pipeline Overview
3. Atopic Dermatitis Phase 3 Clinical Trial Drug Pipeline Insights
4. Atopic Dermatitis Phase 2 Clinical Trial Drug Pipeline Insights
5. Atopic Dermatitis Phase 1 Clinical Trial Drug Pipeline Insights
6. Atopic Dermatitis Preclinical Research Drug Pipeline Insights
7. Atopic Dermatitis Drug Discovery Pipeline Insights
8. Geographic Landscape of Atopic Dermatitis R&D Activities
8.1 Atopic Dermatitis R&D Activities in North America
8.2 Atopic Dermatitis R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Atopic Dermatitis Drug Market
10 Research Methodology
Table 1: Atopic Dermatitis Drug Pipeline: Phase 3 Clinical Trial
Table 2: Atopic Dermatitis Drug Pipeline: Phase 2 Clinical Trial
Table 3: Atopic Dermatitis Drug Pipeline: Phase 1 Molecules
Table 4: Atopic Dermatitis Drug Pipeline: Preclinical Research
Table 5: Atopic Dermatitis R&D Activities by Geography
Table 6: Atopic Dermatitis Drug Pipeline: North America
Table 7: Atopic Dermatitis Drug Pipeline: Europe
Table 8: Atopic Dermatitis Drug Pipeline: Licensing Activities
Figure 1 : Atopic Dermatitis Drug Pipeline Molecules by Stages
Figure 2 : Atopic Dermatitis R&D Activities by Geography

Customers who bought this item also bought